Alerta

BIOMIMETIC PROTEOLIPID NANOVESICLES FOR DELIVERY OF NUCLEIC ACIDS

Resumen de: US20260294808A1

Disclosed herein is a biomimetic proteolipid nanovesicle, comprising: an ionizable or cationic lipid; a phosphocholine-based phospholipid; a cholesterol; a leukocyte membrane protein; and an siRNA encapsulated by the biomimetic proteolipid nanovesicle; wherein the biomimetic proteolipid nanovesicle has a lipid-to-protein ratio of from about 1:65 to about 1:85 by weight. Further disclosed herein is a biomimetic proteolipid nanovesicle, comprising: an ionizable or cationic lipid; a phosphocholine-based phospholipid; a cholesterol; a leukocyte membrane protein; and an mRNA encapsulated by the biomimetic proteolipid nanovesicle; wherein the biomimetic proteolipid nanovesicle has a lipid-to-protein ratio of from about 1:80 to about 1:100 by weight.

PRIMATE CARBONIC ANHYDRASE IV BINDING PEPTIDES AND AAVS

Resumen de: US20260294834A1

0000 Disclosed herein include novel blood-brain barrier (BBB)-crossing receptors on the BBB interface, targeting peptides and derivatives thereof capable of binding to the novel receptors, and related methods of using the receptors to increase the permeability of the BBB and to deliver an agent to a nervous system (e g. CNS).

INFLUENZA EHEAD IMMUNOGENS

Resumen de: US20260295029A1

0000 The present invention relates to influenza immunogens and a vaccine platform for influenza viruses. In particular, the invention relates to a non-naturally occurring polypeptides comprising an engineered hemagglutinin lateral patch sequence and a secretion signal sequence, nucleic acids encoding the same, vectors containing the nucleic acids, nanoparticles containing the polypeptides, nucleic acids or vectors, cells containing the nanoparticles, polypeptides, nucleic acids or vectors, pharmaceutical compositions comprising the cells, nanoparticles, polypeptides, nucleic acids or vectors, vaccines comprising the pharmaceutical compositions and methods for immunization with the vaccines.

CORTICOSTEROID NANOSUSPENSIONS AND USES THEREOF

Resumen de: US20260294934A1

0000 Suspension formulations of nanoparticles of clobetasol propionate are described. The suspensions can be used therapeutically to treat skin and ocular burns; to enhance wound healing; to prevent or reduce hypertrophic scarring/keloids; to treat allergic rhinitis/sinusitis, asthma, inner ear disorders including hearing loss, tinnitus, or vertigo, tenosynovitis, tendinitis, enthesitis or arthritis.

METHOD FOR TARGETING LIPID NANOVESICLES TO SPLEEN AND COMPOSITION THEREFOR

Resumen de: US20260295032A1

0000 The present disclosure relates to a method of delivering a molecule of interest to the spleen. The present disclosure also relates to a method of delivering lipid nanoparticles to the spleen. The present disclosure further relates to a method of inducing antigen-specific immunity in a subject. The present disclosure comprises using a cationic polymer simultaneously with or before the administration of a lipid nanovesicle encapsulating the molecule of interest.

MODIFIED DELIVERY VECTOR AND USE THEREOF

Resumen de: US20260295082A1

0000 The present invention relates to a modified delivery carrier and use thereof. The modified delivery carrier comprises a delivery carrier and a targeting domain coupled to the delivery carrier, wherein the delivery carrier is used for loading an agent, and the targeting domain is capable of specifically targeting a surface antigen of an immune cell.

CALIXARENE-BASED DELIVERY SYSTEM AND METHOD OF USE

Resumen de: US20260294828A1

The current invention relates to a delivery system to deliver one or more cargo to one or more cells, wherein the cargo delivery system comprises at least a calixarene, a phospholipid, an additional lipid such as sterol. The invention further relates to a method of delivering cargo to a subject using the delivery system and a pharmaceutical composition comprising the delivery system. The invention also relates to the use of a calixarene in an immunogenic composition, wherein said composition comprises an immunogenic component encapsulated in a lipid nanoparticle (LNP) comprising said calixarene and wherein said LNP has an adjuvant effect in said immunogenic composition. The invention also relates to a vaccine, wherein said vaccine comprises an immunogenic component encapsulated in a lipid nanoparticle, wherein said lipid nanoparticle comprises at least one calixarene molecule and said lipid nanoparticle acts as an adjuvant in said vaccine. The invention also relates to a method of preparing an immunogenic composition and a composition comprising a lipid nanoparticle (LNP) adjuvant comprising calixarene.

NANOPARTICLE COMPOSITION FOR OXYGEN DELIVERY

Resumen de: US20260294827A1

The present disclosure in some aspects relates generally to nanoparticle compositions for oxygen delivery, method of use thereof, and method of preparation thereof. The present disclosure in some aspects relates generally to topical formulations capable of delivering oxygen to a tissue and methods of their use for treating diseases, such as hypoxemia.

POLYMER NANOPARTICLE COMPOSITIONS FOR NON-VIRAL GENE DELIVERY

Resumen de: US20260295072A1

The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering circRNA.

PHOTOACTIVATABLE NANOPARTICLES AND USES THEREOF AS AGENTS FOR IMMUNOTHERAPY COMBINATIONS

Resumen de: US20260295050A1

0000 Lipid nanoparticles described herein are useful in photodynamic therapy (PDT), a light-activated cancer treatment that uses photosensitizers (PSs) to generate reactive oxygen species (ROS), leading to tumor cell death. These lipid nanoparticles are capable of producing varying levels of oxygen-based radicals and singlet oxygen. In preferred embodiments, the lipid nanoparticles are verteporfin-lipid nanoparticles. Fine-tuning design features of the lipid nanoparticles, such as Type I ROS generation and predominantly ER and mitochondrial localization, provides a more robust induction of immunogenic cell death (ICD).

New composition and method for green manufacture of robust, stable and monodisperse drug carriers using the improved Mozafari method at ambient temperature.

Resumen de: AU2025201666A1

Title of the invention: New composition and method for green manufacture of robust, stable and monodisperse drug carriers using the improved Mozafari method at ambient temperature Inventors: Elham TAGHAVI; Marcel Reza MOZAFARI; Nasim REIHANI; Ali AL-SAMYDAI The embodiments herein provide a new formulation and method for robust manufacturing of various stable micro- and nano-carrier systems for the encapsulation of bioactive agents, pharmaceuticals, minerals and other compounds. According to one embodiment herein, a fine- tuned composition of pharmaceutical ingredients, excipients, solvents, co-solvents, antioxidants, lipids, helper-lipids, sterols and alike, along with one or more active compound(s) is introduced. The combination of the mentioned ingredients is selected such that the combined phase transition temperature of the carrier system is substantially below room temperature. According to another embodiment presented here an easily scalable method is introduced for producing a microcarrier or nanocarrier complex of a pharmaceutical or biological or food or other molecules and compounds disposed within a micro- or nano-carrier system. Whereas the currently available green-procedure for large-scale manufacture of carrier complexes / encapsulation systems known as Mozafari method has the limitation of using moderately high temperatures, the improved Mozafari method can be practiced at any room temperature (even below 20°C). The method, hence, can be applied to all known

GM2 ACTIVATOR VECTORS AND METHODS FOR USE THEREOF

Resumen de: US20260297618A1

0000 This disclosure relates to nucleic acid constructs for expression of GM2 activator (GM2A) protein, and viral vectors comprising said constructs useful for the treatment of AB-variant GM2 Gangliosidosis (ABGM2). Also provided are methods and uses of the vectors disclosed herein for the treatment of ABGM2.

RECONSTITUTABLE DRY POWDER FORMULATIONS AND METHODS OF USE THEREOF

Resumen de: US20260294818A1

0000 The present disclosure is directed to the use of reconstituted mRNA dry powder particles for parenteral administration. The present disclosure is also directed to a method of generating dry powder particles supplemented with appropriate excipients for optimal thermostability and in vivo expression.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: US20260294935A1

Provided herein are lipid nanoparticles comprising cationic steroid compound, as well as the preparation and uses of such lipid nanoparticles. Such lipid nanoparticles are useful in the delivery of payloads, such as nucleic acids, in vivo to non-hepatic organs (e.g., lung) for the treatment or prevention of certain diseases or disorders, particularly lung diseases.

ANTIDIABETIC PHARMACEUTICAL COMPOSITION

Resumen de: US20260294823A1

A pharmaceutical composition includes therapeutic nanoparticles including a core including insulin, a shell comprising chitosan, the shell disposed on the core, and a coating containing pectin and dextrin on the shell, and a pharmaceutically acceptable carrier and/or excipient. A method of forming the pharmaceutical composition includes adding a sodium tri-polyphosphate solution to a chitosan solution including the chitosan and acetic acid while stirring to form a shell solution, mixing a dextrin solution with an insulin solution to form a core solution, forming a pectin solution, mixing the shell solution, the core solution, and the pectin solution using a homogenizer to form a precursor mixture, aging the precursor mixture to form the nanoparticles, and mixing the nanoparticles with the pharmaceutically acceptable carrier and/or excipient.

PROTEIN-BASED DRUG PRODUCTS USING MONOESTER-FREE POLYSORBATE DETERGENT

Resumen de: US20260294831A1

0000 Compositions include a biological component and polysorbate, where the polysorbate is free of monoesters. The invention also provides pharmaceutically acceptable carriers and buffers comprising monoester-free polysorbate, detergent-core nanoparticles comprising monoester-free polysorbate, methods for producing the monoester-free polysorbate, and methods of manufacturing the pharmaceutical compositions using a monoester-free polysorbate.

GLUCONIC ACID-COATED SELENIUM NANOPARTICLES AND MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SELENIUM NANOPARTICLE AND APPLICATIONS THEREOF

Resumen de: US20260294824A1

The present invention provides a gluconic acid-coated selenium nanoparticle (GA-SeNP), which comprises a selenium nanoparticle and gluconic acid, wherein the gluconic acid is coated on the selenium nanoparticle to form a core-shell structure. GA-SeNPs can repolarize M2 macrophages into M1 macrophages and induce apoptosis of cancer cells through the generation of reactive oxygen species, thereby serving as the medicine for cancer treatment. A manufacturing method thereof is also provided.

GINGEROL FORMULATION AND METHODS FOR TREATING CANCER AND BACTERIAL INFECTION

Resumen de: US20260294841A1

0000 A method of reducing cell viability of colon cancer cells includes contacting an encapsulated gingerol composition with the colon cancer cells at a concentration of 15 to 100 μg/mL, wherein the encapsulated gingerol composition comprises gingerol nanoparticles extracted from Zingiber officinale, an ionic cross-linker, a polysorbate, and chitosan nanoparticles, wherein the ionic cross-linker is bonded to the chitosan. The encapsulated gingerol composition is a powder comprising nanoparticles having an average particle size of less than 100 nm, and contacting the encapsulated gingerol composition with the colon cancer cells reduces the cell viability of the colon cancer cells to 40% or less. A method of treating a bacterial infection with the encapsulated gingerol composition.

POLYMER NANOPARTICLE COMPOSITIONS FOR NON-VIRAL GENE DELIVERY

Resumen de: US20260294832A1

0000 The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering RNAs.

TREM COMPOSITIONS AND METHODS OF USE

Resumen de: US20260297575A1

0000 The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

IONIZABLE LIPID COMPOUND, LIPID CARRIER COMPRISING SAME, AND APPLICATION

Resumen de: US20260294810A1

0000 The present invention relates to an ionizable lipid compound, a lipid carrier comprising same, and an application of the ionizable lipid compound. The present invention provides a series of compounds as shown in formula (1), a lipid carrier comprising same as an ionizable lipid, a nucleic acid lipid nanoparticle composition, and a preparation thereof. Lipid nanoparticles formed by the ionizable lipid can deliver nucleic acid molecules into cells, thus increasing the transfer rate of the nucleic acid molecules, and thereby improving the treatment effect of a nucleic acid drug. 0000

MAGNETICALLY DRIVENABLE ANTIGEN DELIVERY UNIT AND METHOD OF FORMING SAME

Resumen de: US20260294821A1

0000 A magnetically drivenable antigen delivery unit is disclosed as including a magnetic nanoparticle to which an antigen is loaded, and a biodegradable material encapsulating the magnetic nanoparticle. A method of forming a magnetically drivenable antigen delivery unit using microfluidic droplet generation technique is disclosed as including forming a solution of a magnetic nanoparticle to which an antigen is loaded, gelatin methacryloyl (GelMA), and lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP). The invention also discloses a method for realizing lymph node targeted delivery by magnetically driving subunit antigens.

UNIVERSAL TREATMENT OF DOWN SYNDROME

Resumen de: US20260294978A1

Allele-specific (AS) CRISPR-Cas9-mediated cleavage to induce selective loss of the extra chromosome, particularly in a trisomic context where the dosage imbalance is inherently deleterious, can treat Down Syndrome, an untreatable disorder. While it is suitable for individualized therapy, the instant invention provides a generalized treatment module that can be used for any Down Syndrome patient.

ADIPOSE TARGETING PEPTIDES, COMPOSITIONS, AND METHODS OF USE THEREOF

Resumen de: US20260295070A1

0000 The present invention provides peptides that selectively target adipose tissue and adipose stromal stem cells (ASCs). Accordingly, in some embodiments, the invention provides compositions and methods for selective delivery of compounds to adipose tissue and ASCs and methods of treating diseases and disorders through targeted compound delivery.

LIPIDS AND NANOPARTICLE FORMULATIONS THEREOF

Nº publicación: US20260295080A1 01/10/2026

Solicitante:

ARCTURUS THERAPEUTICS INC [US]
Arcturus Therapeutics, Inc.

Resumen de: US20260295080A1

The present disclosure relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods thereof.